Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Michael B Horsley, Malik Y KahookRocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO, USAPurpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Michael B Horsley, Malik Y Kahook
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/e7c879c638b04f038a3d0a356839b42a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e7c879c638b04f038a3d0a356839b42a
record_format	dspace
spelling	oai:doaj.org-article:e7c879c638b04f038a3d0a356839b42a2021-12-02T00:56:12ZEffects of prostaglandin analog therapy on the ocular surface of glaucoma patients1177-54671177-5483https://doaj.org/article/e7c879c638b04f038a3d0a356839b42a2009-03-01T00:00:00Zhttp://www.dovepress.com/effects-of-prostaglandin-analog-therapy-on-the-ocular-surface-of-glauc-a2994https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Michael B Horsley, Malik Y KahookRocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO, USAPurpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching therapy from latanoprost with 0.02% benzalkonium chloride (BAK) to travoprost with sofZia&trade;.Methods: Prospective consecutive case series evaluating patients before and 8 weeks after switching from latanoprost with BAK to travoprost with sofZia&trade; in patients with baseline TBUT less than 6 seconds.Results: Forty eyes of 20 consecutive patients using latanoprost with BAK were switched to travoprost with sofZia&trade;. Mean TBUT prior to starting travoprost was 2.02 &plusmn; 0.71 seconds and increased to 6.34 &plusmn; 1.31 seconds 8 weeks after the switch (p&nbsp;&lt; 0.001). Mean inferior corneal staining scores decreased from 2.40 &plusmn; 0.87 to 1.38 &plusmn; 0.59 (p &lt; 0.001). Mean OSDI scores decreased from 26.31 &plusmn; 8.25 to 16.56 &plusmn; 6.19 (p &lt;&nbsp;0.001).Discussion: This report focuses on the status of the ocular surface, as documented by TBUT, corneal staining and OSDI, in patients switched from latanoprost with BAK to travoprost without BAK. The switch resulted in a statistically significant increase in TBUT and decreases in corneal staining and OSDI in patients with low baseline TBUT values.Conclusion: BAK, a common preservative for glaucoma drops, may increase OSD by disrupting the tear film and increasing conjunctival inflammation. In this study, a change from a BAK-preserved prostaglandin analog (PGA) to a non-BAK-preserved PGA resulted in a measurable improvement of TBUT, corneal staining and OSDI. Further studies are needed to better understand the impact of BAK-preserved medications on the ocular surface.Keywords: ocular surface, glaucoma, benzalkonium chloride, prostaglandin analog Michael B HorsleyMalik Y KahookDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 291-295 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Michael B Horsley Malik Y Kahook Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
description	Michael B Horsley, Malik Y KahookRocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO, USAPurpose: To quantify changes in tear break-up time (TBUT), corneal staining and ocular surface disease index (OSDI) in glaucoma patients after switching therapy from latanoprost with 0.02% benzalkonium chloride (BAK) to travoprost with sofZia&trade;.Methods: Prospective consecutive case series evaluating patients before and 8 weeks after switching from latanoprost with BAK to travoprost with sofZia&trade; in patients with baseline TBUT less than 6 seconds.Results: Forty eyes of 20 consecutive patients using latanoprost with BAK were switched to travoprost with sofZia&trade;. Mean TBUT prior to starting travoprost was 2.02 &plusmn; 0.71 seconds and increased to 6.34 &plusmn; 1.31 seconds 8 weeks after the switch (p&nbsp;&lt; 0.001). Mean inferior corneal staining scores decreased from 2.40 &plusmn; 0.87 to 1.38 &plusmn; 0.59 (p &lt; 0.001). Mean OSDI scores decreased from 26.31 &plusmn; 8.25 to 16.56 &plusmn; 6.19 (p &lt;&nbsp;0.001).Discussion: This report focuses on the status of the ocular surface, as documented by TBUT, corneal staining and OSDI, in patients switched from latanoprost with BAK to travoprost without BAK. The switch resulted in a statistically significant increase in TBUT and decreases in corneal staining and OSDI in patients with low baseline TBUT values.Conclusion: BAK, a common preservative for glaucoma drops, may increase OSD by disrupting the tear film and increasing conjunctival inflammation. In this study, a change from a BAK-preserved prostaglandin analog (PGA) to a non-BAK-preserved PGA resulted in a measurable improvement of TBUT, corneal staining and OSDI. Further studies are needed to better understand the impact of BAK-preserved medications on the ocular surface.Keywords: ocular surface, glaucoma, benzalkonium chloride, prostaglandin analog
format	article
author	Michael B Horsley Malik Y Kahook
author_facet	Michael B Horsley Malik Y Kahook
author_sort	Michael B Horsley
title	Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
title_short	Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
title_full	Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
title_fullStr	Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
title_full_unstemmed	Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
title_sort	effects of prostaglandin analog therapy on the ocular surface of glaucoma patients
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/e7c879c638b04f038a3d0a356839b42a
work_keys_str_mv	AT michaelbhorsley effectsofprostaglandinanalogtherapyontheocularsurfaceofglaucomapatients AT malikykahook effectsofprostaglandinanalogtherapyontheocularsurfaceofglaucomapatients
_version_	1718403411431391232

Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients

Ejemplares similares